Formulation and Pharmacological Studies of Leaves of Moringa (Moringa oleifera), a Novel Hepatoprotection in Oral Drug Formulations

Aristianti Aristianti; Nurkhaeri Nurkhaeri; Vanny Y. Tandiarrang; Akbar Awaluddin; Lukman Muslimin

doi:10.3889/oamjms.2021.5839

Authors

Aristianti Aristianti 1Department of Pharmacology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Nurkhaeri Nurkhaeri Department of Pharmaceutical Technology, Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia
Vanny Y. Tandiarrang Department of Pharmaceutical Technology, Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia
Akbar Awaluddin Department of Pharmacology, Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia
Lukman Muslimin Department of Pharmaceutical Chemistry, Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.5839

Keywords:

Hepatoprotection, Leaves, Moringa oleifera, Suspension

Abstract

BACKGROUND: Moringa oleifera, Moringaceae, is a tree that is native to South East Asia. Various parts of this tree are commonly used in traditional medicine to treat inflammation, hepatitis, gastric ulcer, and other ailments.

AIM: M. oleifera leaves extract was formulated into stable suspensions, characterized, and then evaluated for hepatoprotection activity against isoniazid.

MATERIALS AND METHODS: The leaves were extracted using cold maceration, and suspensions of extract were prepared using sodium carboxymethyl cellulose (Na-CMC) as suspension agent at various concentrations (0.1, 0.5, and 1.0%). The formulations were analyzed by their appearance, color, odor, and taste. Density, pH, viscosity, re-dispersibility test, and sedimentation volume were observed. The stability of oral suspensions was analyzed in accelerated studies (5°C ± 2°C and 35°C ± 2°C for 12 h for 7 cycles) to find stable formulation, while the hepatoprotection activity was analyzed using an in vivo isoniazid-induced model.

RESULTS: The appearance, color, odor, and taste of the suspensions were shown to be characteristic of the extract. Na-CMC at concentration 0.5% showed good physical properties. Stable suspension at dose 400 mg/kg BW per oral for 28 days exhibited a significant (p < 0.05) decrease in the serum glutamate oxaloacetate transaminase and serum glutamate pyruvate transaminase.

CONCLUSION: Suspension containing M. oleifera leaves extract at 50 mg/5 mL was successfully obtained and showed physical properties that were appropriate and characteristic of this dosage form, suitable for hepatoprotection (400 mg/kg BW), making this an alternative to tablets.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

World Health Organization. Tuberculosis. Geneva: World Health Organization; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. [Last accessed on 2021 Jan 30].

Susilawati TN, Larasati R. A recent update of the diagnostic methods for tuberculosis and their applicability in indonesia: A narrative review. Med J Indones. 2019;28(3):284-91. https://doi.org/10.13181/mji.v28i3.2589 DOI: https://doi.org/10.13181/mji.v28i3.2589

Sotgiu G, Centis R, D’Ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015;5(5):a017822. https://doi.org/10.1101/cshperspect.a017822 PMid:25573773 DOI: https://doi.org/10.1101/cshperspect.a017822

Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J Bras Pneumol. 2010;36(5):626-40. PMid:21085830 DOI: https://doi.org/10.1590/S1806-37132010000500016

Geremew D, Endalamaw A, Negash M, Eshetie S, Tessema B. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: A meta-analysis. BMC Infect Dis. 2019;19(1):405. https://doi.org/10.1186/s12879-019-4031-2 PMid:31077133 DOI: https://doi.org/10.1186/s12879-019-4031-2

Yadav B, Gunnam A, Thipparaboina R, Nangia AK, Shastri NR. Hepatoprotective cocrystals of isoniazid: Synthesis, solid state characterization, and hepatotoxicity studies. Cryst Growth Des. 2019;19(9):5161-72. https://doi.org/10.1021/acs.cgd.9b00541 DOI: https://doi.org/10.1021/acs.cgd.9b00541

Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: Then and now. Br J Clin Pharmacol. 2016;81(6):1030-6. PMid:26773235

Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21(1):1-20. https://doi.org/10.1111/bcp.12885 PMid:27842765 DOI: https://doi.org/10.1111/bcp.12885

Underhill GH, Khetani SR. Advances in engineered human liver platforms for drug metabolism studies. Drug Metab Dispos. 2018;46(11):1626-37. https://doi.org/10.1124/dmd.118.083295 PMid:30135245 DOI: https://doi.org/10.1124/dmd.118.083295

Biswas A, Santra S, Bishnu D, Dhali GK, Chowdhury A, Santra A. Isoniazid and rifampicin produce hepatic fibrosis through an oxidative stress-dependent mechanism. Int J Hepatol. 2020;2020:6987295. https://doi.org/10.1155/2020/6987295 PMid:32373368 DOI: https://doi.org/10.1155/2020/6987295

Cheng DL, Zhu N, Li CL, Lv WF, Fang WW, Liu Y, et al. Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model. Exp Ther Med. 2018;16(6):5227-35. https://doi.org/10.3892/etm.2018.6835 PMid:30542478 DOI: https://doi.org/10.3892/etm.2018.6835

Villarruel-López A, López-de la Mora DA, Vázquez-Paulino OD, Puebla-Mora AG, Torres-Vitela MR, Guerrero-Quiroz LA, et al. Effect of Moringa oleifera consumption on diabetic rats. BMC Complement Altern Med. 2018;18:127. https://doi.org/10.1186/s12906-018-2180-2 PMid:29636032 DOI: https://doi.org/10.1186/s12906-018-2180-2

Jahan IA, Hossain MH, Ahmed KS, Sultana Z, Biswas PK, Nada K. Antioxidant activity of Moringa oleifera seed extracts. Orient Pharm Exp Med. 2018;18(4):299-307. https://doi.org/10.1007/s13596-018-0333-y DOI: https://doi.org/10.1007/s13596-018-0333-y

Al-Asmari AK, Albalawi SM, Athar MT, Khan AQ, Al-Shahrani H, Islam M. Moringa oleifera as an anti-cancer agent against breast and colorectal cancer cell lines. PloS One. 2015;10:e0135814. https://doi.org/10.1371/journal.pone.0135814 PMid:26288313 DOI: https://doi.org/10.1371/journal.pone.0135814

Xu YB, Chen GL, Guo MQ. Antioxidant and anti-inflammatory activities of the crude extracts of Moringa oleifera from Kenya and their correlations with flavonoids. Antioxidants (Basel). 2019;8:296. https://doi.org/10.3390/antiox8080296 PMid:31404978 DOI: https://doi.org/10.3390/antiox8080296

Panche AN, Diwan AD, Chandra SR. Flavonoids: An overview. J Nutr Sci. 2016;5:e47. PMid:28620474 DOI: https://doi.org/10.1017/jns.2016.41

Nguyen TP, Tran CL, Vuong CH, Do TH, Le TD, Mai DT, et al. Flavonoids with hepatoprotective activity from the leaves of Cleome viscosa L. Nat Prod Res. 2017;31(22):2587-92. https://doi.org/10.1080/14786419.2017.1283497 PMid:28135851 DOI: https://doi.org/10.1080/14786419.2017.1283497

Ekundina VO, Ebeye OA, Oladele AA, Osham GO. Hepatotoxic and nephrotoxic effects of Moringa oleifera leaves extract in adult Wistar rats. J Nat Sci Res. 2015;5(3):110-7.

Kittipongpatana O, Sirithunyalug J. Development of suspending agent from sodium carboxymethyl mungbean starches. Drug Dev Ind Pharm. 2006;32(7):809-20. https://doi.org/10.1080/03639040500529978 PMid:16908418 DOI: https://doi.org/10.1080/03639040500529978

Kittipongpatana OS, Burapadaja S, Kittipongpatana N. Carboxymethyl mungbean starch as a new pharmaceutical gelling agent for topical preparation. Drug Dev Ind Pharm. 2009;35(1):34-42. https://doi.org/10.1080/03639040802144229 PMid:18720150 DOI: https://doi.org/10.1080/03639040802144229

Doye P, Mena T, Das N. Formulation and bio-availability parameters of pharmaceutical suspension. Int J Curr Pharm Res. 2017;9(3):8-14. https://doi.org/10.22159/ijcpr.2017.v9i3.18892 22. Kumar R, Rajarajeshwari N, Swamy VB. Isolation and evaluation of Borassus flabellifer mucilage as a natural suspending agent. Int J Pharmtech Res. 2012;4(4):1614-30.

Ahn JY, Kim JM, Jeong TS, Kim S. A study on the effect of syrup form medicines for children on intraoral pH. J Korean Acad Pediatr Dent. 2007;34(4):590-8.

Patel D, Bertz R, Ren S, Boulton DW, Någård M. A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. Clin Pharmacokinet. 2020;59(4):447-62. https://doi.org/10.1007/s40262-019-00844-3 PMid:31788764 DOI: https://doi.org/10.1007/s40262-019-00844-3

Wang P, Pradhan K, Zhong X-b, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6(5):384-92. PMid:27709007 DOI: https://doi.org/10.1016/j.apsb.2016.07.014

Hassan H, Hongli G, Yousef B, Luyong Z, Jiang Z. Hepatotoxicity mechanisms of isoniazid: A mini-review. J Appl Toxicol. 2015;35(12):1427-32. https://doi.org/10.1002/jat.3175 PMid:26095833 DOI: https://doi.org/10.1002/jat.3175

Elvira-Torales LI, García-Alonso J, Periago-Castón MJ. Nutritional importance of carotenoids and their effect on liver health: A review. Antioxidants (Basel). 2019;8(7):229. https://doi.org/10.3390/antiox8070229 PMid:31330977 DOI: https://doi.org/10.3390/antiox8070229